Durect Corporation (DRRX)

Currency in USD
1.9100
-0.0200(-1.04%)
Closed·
Showing Durect historical data. For real-time data please try another search
Fair Value
Day's Range
1.91001.9500
52 wk Range
0.48012.6400
Key Statistics
Prev. Close
1.91
Open
1.93
Day's Range
1.91-1.95
52 wk Range
0.4801-2.64
Volume
2.79M
Average Volume (3m)
1.21M
1-Year Change
46.92%
Book Value / Share
0.11
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DRRX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.

Durect Corporation News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Durect Corporation Company Profile

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company’s lead product candidate includes larsucosterol, an endogenous, orally bioavailable small molecule to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as for the treatment of patients with metabolic dysfunction-associated steatohepatitis. The company also offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; PERSERIS, an injectable suspension for the treatment of schizophrenia in adults; and Methydur to treat attention deficit hyperactivity disorder. It has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California. As of September 11, 2025, DURECT Corporation operates as a subsidiary of Bausch Health Americas, Inc.

Employees
13

Durect Corporation Earnings Call Summary for Q4/2024

  • Q4 2024 revenue fell to $500,000 from $900,000 YoY; 2024 total revenue dropped to $2M from $2.6M in 2023
  • Durect became debt-free after repaying term loan; cash reserves of $12M expected to sustain operations through Q3 2025
  • Focus shifts to Larcicosterol for alcohol-associated hepatitis; Phase 3 trial estimated at $20M, exploring funding options
  • R&D expenses reduced to $10.4M in 2024 from $29.4M in 2023; SG&A expenses down to $10M from $12.7M
  • Analysts set price targets of $5-$8.50, indicating upside potential despite current financial challenges
Last Updated: 26/03/2025, 22:18
Read Full Transcript

Compare DRRX to Peers and Sector

Metrics to compare
DRRX
Peers
Sector
Relationship
P/E Ratio
−4.5x0.0x−0.7x
PEG Ratio
−0.060.000.00
Price/Book
17.0x0.0x2.6x
Price / LTM Sales
35.8x0.0x3.4x
Upside (Analyst Target)
30.9%0.0%35.7%
Fair Value Upside
Unlock0.0%4.1%Unlock

Earnings

Latest Release
Aug 12, 2025
EPS / Forecast
-0.07 / -0.12
Revenue / Forecast
447.00K / --
EPS Revisions
Last 90 days

DRRX Income Statement

People Also Watch

91.55
CALM
-0.62%
5.04
PEPG
+3.49%
3.170
MBOT
-3.65%
11.000
CRMD
-2.40%
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.